시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 인테그라제 억제제 시장 보고서(2025년)
Integrase Inhibitors Global Market Report 2025
상품코드 : 1760571
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,693,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,675,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,656,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

인테그라제 억제제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 6.7%의 성장률(CAGR)로 61억 달러에 달할 것으로 예측됩니다. 향후 HIV 감염자 증가, HIV 치료 옵션에 대한 인식 증가, 예방 요법의 확대, 장기 지속형 주사제의 부상, 보험 및 상환 범위의 확대 등이 예측 기간 동안 성장을 견인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 지속형 주사제 채택, 디지털 및 원격 의료 서비스 통합, 개인화된 HIV 치료 접근법, 기술 발전, 소아 치료제 개발 등이 있습니다.

HIV 감염률 증가는 인테그라제 억제제 시장의 성장을 가속할 것으로 예상되며, HIV는 인간 면역 결핍 바이러스에 의한 장기적인 바이러스 감염으로 CD4+ T 세포를 표적으로 삼고 파괴하여 면역 체계를 손상시켜 다른 질병에 대한 취약성을 증가시킵니다. HIV 감염자 증가는 양질의 의료서비스에 대한 접근성 부족이 주요 원인이며, 특히 의료 서비스를 충분히 받지 못하는 사람들의 예방, 진단, 치료 노력이 제한되어 있습니다. 인테그라제 억제제는 HIV 치료에서 바이러스가 인간 DNA에 유전물질을 삽입하는 것을 막음으로써 바이러스의 복제를 억제하고 감염을 통제하는 데 중요한 역할을 합니다. 예를 들어, 2024년 10월 gov.uk에 따르면 영국에서는 2023년 6,008건의 신규 HIV 진단이 기록되어 2022년 3,975건보다 51% 증가하였습니다.

인테그라제 억제제 시장의 주요 기업들은 환자의 복약 순응도를 높이고, 사용 편의성을 개선하며, 항레트로바이러스 약물의 안전하고 효율적인 투여를 보장하기 위해 단위 용량 포장과 같은 혁신적인 포장 솔루션에 집중하고 있으며, 특히 장기 HIV 치료를 받고 있는 환자들을 대상으로 하고 있습니다. 단위 용량 포장은 용량이 개별적으로 밀봉되어 있어 정확한 투약, 취급 용이성, 약물의 안전성 향상을 지원합니다. 예를 들어, 2024년 2월 영국의 HIV 치료제 전문 제약사 비브헬스케어는 블리스터 팩 형태의 도바토(돌테그라비르/라미부딘)를 미국에서 출시했습니다. 이 제품은 항레트로바이러스 치료를 처음 받거나 바이러스학적으로 억제된(HIV-1 RNA <50 copies/mL) 성인 HIV-1 환자 중 과거 치료 실패 경험이 없고 도바토의 성분에 대한 내성이 없는 환자를 위한 완전 요법으로 승인됐습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

LSH
영문 목차

영문목차

Integrase inhibitors are a class of antiretroviral drugs that block the action of the HIV enzyme integrase, preventing the integration of viral DNA into the host cell's genome. This inhibition stops the replication of the virus and slows the progression of HIV infection. These inhibitors are primarily used in the treatment of HIV, typically as part of combination therapy to lower viral load and enhance immune function.

The main drug types within integrase inhibitors include raltegravir, dolutegravir, elvitegravir, and bictegravir. Raltegravir is an antiretroviral medication that treats HIV-1 infection by inhibiting the integrase enzyme, thereby preventing the virus from integrating its genetic material into the host's DNA. These drugs are administered through various routes, including oral, intravenous, and subcutaneous, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Their therapeutic indications include HIV infection, HCV infection, and other viral infections. The key end users of these drugs are hospitals, clinics, and research institutions.

The integrase inhibitors market research report is one of a series of new reports from The Business Research Company that provides integrase inhibitors market statistics, including the integrase inhibitors industry global market size, regional shares, competitors with the integrase inhibitors market share, detailed integrase inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the integrase inhibitors industry. This integrase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The integrase inhibitors market size has grown strongly in recent years. It will grow from $4.40 billion in 2024 to $4.71 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising prevalence of HIV, increased global awareness and improvements in treatment, government initiatives and funding, a rise in HIV diagnoses and testing, and the aging HIV population.

The integrase inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.10 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. Looking ahead, growth in the forecast period is expected to be driven by an increase in HIV infections, greater awareness about HIV treatment options, the expansion of preventive therapies, the rise of long-acting injectable treatments, and the expansion of insurance and reimbursement coverage. Key trends expected during this period include the adoption of long-acting injectables, integration of digital and telehealth services, personalized HIV treatment approaches, technological advancements, and the development of pediatric formulations.

The increasing prevalence of HIV infections is anticipated to drive the growth of the integrase inhibitors market. HIV is a long-term viral infection caused by the human immunodeficiency virus, which compromises the immune system by targeting and destroying CD4+ T cells, thereby heightening vulnerability to other illnesses. The rise in HIV cases is largely attributed to inadequate access to quality healthcare, which limits prevention, diagnostic, and treatment efforts, particularly in underserved populations. Integrase inhibitors play a key role in HIV therapy by preventing the virus from integrating its genetic material into human DNA, thereby suppressing viral replication and aiding in infection control, which may contribute to reducing HIV prevalence. For example, in October 2024, gov.uk reported that England recorded 6,008 new HIV diagnoses in 2023, a 51% increase from 3,975 cases in 2022. Thus, the growing number of HIV infections is expected to support the expansion of the integrase inhibitors market.

Leading companies in the integrase inhibitors market are concentrating on innovative packaging solutions, such as unit dose packaging, to promote patient adherence, enhance ease of use, and ensure the secure and efficient administration of antiretroviral drugs, particularly for individuals undergoing long-term HIV treatment. Unit dose packaging involves individually sealed doses, which support accurate dosing, ease of handling, and improved medication safety. For instance, in February 2024, ViiV Healthcare, a UK-based pharmaceutical company dedicated to HIV treatments, introduced Dovato (dolutegravir/lamivudine) in blister pack form in the United States. This product is approved as a complete regimen for adults with HIV-1 who are either new to antiretroviral therapy or virologically suppressed (HIV-1 RNA <50 copies/mL) with no prior treatment failures or known resistance to Dovato's components.

In April 2024, ViiV Healthcare collaborated with the Medicines Patent Pool (MPP) to broaden access to dolutegravir (DTG)-based HIV medications. This partnership has facilitated the distribution of over one billion packs of generic DTG treatments to 24 million individuals living with HIV across 128 low- and middle-income countries, significantly enhancing accessibility and treatment outcomes. The Medicines Patent Pool, based in Switzerland, is a non-profit organization that negotiates patent licenses to improve access to essential medicines.

Major players in the integrase inhibitors market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bristol-Myers squibb Company, GlaxoSmithKline PLC, Gilead Sciences, Boehringer Ingelheim, Viatris Inc., Hetero Pharmaceuticals, ViiV Healthcare, Apotex, Shionogi Co. ltd., Aurobindo Pharma, Dr. Reddy's Laboratories, Cipla Limited, Lupin Limited, Torii Pharmaceutical Co. Ltd, Theratechnologies Inc., Adooq Bioscience, and Aetos Pharma.

North America was the largest region in the integrase inhibitors market in 2024. The regions covered in integrase inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the integrase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The integrase inhibitors market consists of sales of tablets, capsules, fixed-dose combination drugs, and injectable formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Integrase Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on integrase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for integrase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The integrase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Integrase Inhibitors Market Characteristics

3. Integrase Inhibitors Market Trends And Strategies

4. Integrase Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Integrase Inhibitors Growth Analysis And Strategic Analysis Framework

6. Integrase Inhibitors Market Segmentation

7. Integrase Inhibitors Market Regional And Country Analysis

8. Asia-Pacific Integrase Inhibitors Market

9. China Integrase Inhibitors Market

10. India Integrase Inhibitors Market

11. Japan Integrase Inhibitors Market

12. Australia Integrase Inhibitors Market

13. Indonesia Integrase Inhibitors Market

14. South Korea Integrase Inhibitors Market

15. Western Europe Integrase Inhibitors Market

16. UK Integrase Inhibitors Market

17. Germany Integrase Inhibitors Market

18. France Integrase Inhibitors Market

19. Italy Integrase Inhibitors Market

20. Spain Integrase Inhibitors Market

21. Eastern Europe Integrase Inhibitors Market

22. Russia Integrase Inhibitors Market

23. North America Integrase Inhibitors Market

24. USA Integrase Inhibitors Market

25. Canada Integrase Inhibitors Market

26. South America Integrase Inhibitors Market

27. Brazil Integrase Inhibitors Market

28. Middle East Integrase Inhibitors Market

29. Africa Integrase Inhibitors Market

30. Integrase Inhibitors Market Competitive Landscape And Company Profiles

31. Integrase Inhibitors Market Other Major And Innovative Companies

32. Global Integrase Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Integrase Inhibitors Market

34. Recent Developments In The Integrase Inhibitors Market

35. Integrase Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기